Ewing sarcoma (ES) is the second most common bone malignancy in children and young adults, with a slight male predominance.1 ES has a high propensity to metastasize, and about 25% of patients show disseminated involvement at the beginning of disease. Multimodality treatment approaches, including surgery, radiotherapy (RT), and intensive multidrug chemotherapy, have led to notable improvement in the outcome of patients with localized disease, up to about 70% of event-free survival (EFS).2,3

In contrast, the prognosis of patients with primary disseminated disease remains very poor, with an EFS of <20%.4 Patients with primary pulmonary metastases show a better outcome than patients with primary bone and/or bone marrow involvement.4-8 Conventional treatment regimens for localized ES generally consist of a combination of vincristine, actinomycin-D, cyclophosphamide, doxorubicin, ifosfamide, and etoposide. Adjunctive surgical resection with or without radiation therapy is used for local control. Most episodes of disease recurrence occur after completion of therapy, and most recurrences (approximately 80%) occur within 2 years from initial diagnosis.9 Cisplatin (CDDP) and other platinum compounds are widely used drugs for the treatment of solid tumors in adults and children, especially when failure of first-line therapy occurs, but data concerning its activity and efficacy are very limited in ES.

We describe an impressive response to front-line CDDP as a single drug in a child with metastatic ES with a favorable clinical outcome.

CASE REPORT

A 10-year-old African boy was admitted 10 months after the onset of left elbow pain, followed by progressive swelling. He was diagnosed with an osteosarcoma (small cell variant) of the left arm in a Nigerian Hospital. He did not receive any therapy in Nigeria because they concentrate the few economical resources available on patients with more chances of healing. An international committee organized a transfer abroad to verify the histologic diagnosis and to explore the possibility of a therapeutic approach.

On admission the boy showed a huge mass (circumference 43 cm, whereas the contralateral was 15 cm) in the left elbow, and packed lymph nodes, sized 6 × 8 cm, were palpable in the left armpit (Figs. 1A, B). Other enlarged lymph nodes were palpable just over the left collar-bone. A painful subcutaneous nodule, sized 3 × 2 cm, was palpable in the left shoulder blade region. The left knee compression was painful. The abdomen, heart, and chest were unre markable; no hepatosplenomegaly or skin lesions were observed.

Laboratory findings showed lactic dehydrogenase levels to be 1951 U/L (normal value < 480 U/L).

A computed tomography (CT) scan showed a large osteolytic lesion of the distal humerus and proximal radius and ulna surrounded by proliferating soft tissue. Total body CT scan and 99mTc-MDP bone scan showed a large mass of metastatic packed lymph nodes in the left armpit and skeletal metastases to the proximal region of the left humerus, to the fourth left rib, on the inferior region of the left shoulder blade and on the left knee. Bone marrow biopsy and aspirate were normal.

An open biopsy of the elbow mass was done. Histologically, the tumor was characterized by a monomorphic proliferation of small round cells with regular nuclei, finely dispersed chromatin, and inconspicuous nucleoli (Figs. 2A, B). Cytoplasm was scant and slightly eosinophilic with no matrix production. The tumor grew in a diffuse and sheet-like pattern infiltrating the cortical bone and lamellar bone of periosteal reaction and assumed lobular and filigree pattern in soft tissue invasion with necrosis (Fig. 2C).

The cells showed strong and diffuse membranous immunoreactivity toward cell-surface glycoprotein CD99 (Fig. 2D).

Reverse transcriptase polymerase chain reaction analysis of ES was performed from paraffin-embedded tissue. Molecular studies showed the characteristic translocation leading to a fusion of the ES gene (EWS) on 22q12 as to a member of the ES family transcription factors, which in our case was FLI1.

In conclusion, a diagnosis of ES with multiple skeletal and lymph node metastases was reached. The patient was enrolled in a joint trial of ISG and AIEOP for patients with multicenter ES at onset, called ISG-AIEOP/VHR-EW 02 protocol, consisting of a
front-line with 2 courses of CDDP 100 mg/m² by 48-hour continuous infusion 3 weeks apart, followed by 8 courses of combined chemotherapy, a consolidation phase with myeloablative busulfan + melphalan, and local treatment on the site of the primary tumor, according to the same strategy adopted in the previous ISG/AIEOP VHR-EW 01 protocol, in which the front-line consisted of melphalan.

The front-line CDDP courses were well tolerated without any severe side effect. After the second course of therapy with CDDP, the elbow circumference decreased to 28 cm (Fig. 3A); supraclavicular lymph nodes disappeared and axillary reduced to <1 cm. Levels of lactic dehydrogenase fell below 500 IU/L.

The reevaluation by CT scan of the chest and left arm, total body scan with 99Tc-MDP, and magnetic resonance imaging of the left arm, showed a very good response to treatment, with a very impressive reduction of the primary tumor size and a complete disappearance of the metastatic lymphadenopathy. A residual abnormal uptake in the 99Tc-MDP bone scan on the left knee and left humerus was documented.

The patient underwent a subsequent phase with 8 intensive courses of chemotherapy. Collection of hematopoietic stem cells was done by leukapheresis after first course of cyclophosphamide 4 g/m² + etoposide 600 mg/m² (overall the fourth course), followed by filgrastim at a dose of 10 μg/m²/d, according to the protocol. A total of $4 \times 10^8$ nucleated cells and $8 \times 10^6$ CD34+ cells were collected.

Evaluation after the last course of chemotherapy, preceding the myeloablative treatment, showed an elbow circumference of 17 cm (Fig. 3B), whereas CT scan and magnetic resonance imaging of the elbow confirmed marked reduction of the tumor. Total body bone scan with 99Tc-MDP showed a residual uptake on the left elbow without other metastatic locations.

To obtain the best control of the disease, we proposed demolitive surgery consisting of amputation of the left arm. The mother of the patient refused surgery, and for this reason we decided to give exclusive RT for local control, which was delayed until after the myeloablative phase. The patient received the consolidation phase with busulfan (1 mg/kg × 16 doses) and melphalan (140 mg/m²), followed by autologous peripheral blood stem cell transplantation, with a normal take of polymorphonucleates and thrombocytes and without acute complications.

RT on the site of the primary tumor concluded the treatment program and consisted of 2 fractions of 1.2 Gy/d, up to a total dose of 55.2 Gy. Now, 42 months after the beginning of treatment and 30 months after the end of therapy, the child is well and in continuous complete remission.

FIGURE 1. A, On admission the boy presented an impressive huge mass of the left elbow, having a circumference of about 43 cm. B, Packed lymph nodes, sized $6 \times 8$ cm, were palpable in the left armpit.

FIGURE 2. A and B, The tissue was characterized by a monomorphic proliferation of small round cells with regular nuclei, finely dispersed chromatin, and inconspicuous nucleoli. The cytoplasm was scant and slightly eosinophilic with no matrix production. C, The tumor grew in a diffuse and sheet-like pattern infiltrating the cortical bone and lamellar bone of periosteal reaction and assumed a lobular and filagree pattern in soft tissue invasion with necrosis. D, The cells showed strong and diffuse membranous immunoreactivity toward cell-surface glycoprotein CD99.
DISCUSSION

ES is the second most common bone malignancy in children and young adults, and prognosis of patients with disseminated disease other than pulmonary remains very poor, with an EFS of <25%.

The introduction of combined modality treatment has determined a relevant improvement in the prognosis for many patients with ES. However, the results identified a bad prognosis of patients with large-volume primary tumors and metastatic disease. Our patient had both of these unfavorable prognostic characteristics, because he was admitted to our unit >10 months after the first signs and symptoms. The child, who was referred with a doubtful diagnosis of small cell osteosarcoma, was globally reevaluated, and histologic and molecular diagnosis of ES was correctly reached. The child was enrolled in the ISG-AIEOP/VHR-EW 02 protocol, consisting of a double course of high dose of CDDP window therapy, followed by intensive chemotheraphy, myeloablative regimen, and autologous stem cell rescue. Response to CDDP alone, which is not generally used in clinical trials in first-line therapy, was very impressive, with a marked reduction of primary tumor size and metastatic disease.

In the literature, few phase II studies with CDDP in refractory solid tumors in children are reported, including ES. Overall, in these studies, of 27 patients with ES, only 2 objective responses were observed.11–14 Platinum compounds have been used as first-line therapy in patients with ES, in a very limited number of studies, mostly in combination with other drugs, generally administered at doses of 70 to 100 mg/m², and some authors reported its effectiveness in the preoperative treatment of ES.15–17

In this patient the local treatment on the site of the primary consisted of RT alone. We are aware that a factor influencing the outcome in ES is surgery, which gives better results than RT alone in a nonlocalized ES setting, but surgery was not possible because his mother refused a demolitive surgical approach—arm amputation—because of religious reasons.8

In conclusion, the peculiarity of our case was the great sensitivity of the ES to CDDP. The patient had a favorable outcome and is now a long-term survivor. It is not possible to assess the contribution of the front-line CDDP to this favorable outcome, as this phase was part of an intensive and prolonged treatment approach, but our experience suggests that an aggressive treatment option may be justified even if the possibilities of cure seem extremely slim.

ACKNOWLEDGMENT

The authors thank Prof. Frank Adamo for revising the manuscript.

REFERENCES

1. Ries L, Smith M, Gurney JG, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. Bethesda (MD): National Cancer Institute SEER Program; 1999.
2. Jurgen H, Exner U, Gaidner H, et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial Cancer. 1988;61:23–32.
3. Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8364 Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:125–135.
4. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 1995;15:697–705.
5. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–3114.
6. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–1654.
7. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9:275–281.
8. Haeseler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116:443–450.
9. Laneve P, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the children’s oncology group. Pediatr Blood Cancer. 2006;51:334–338.
10. Luksch R, Grignani G, Fagioli F, et al. Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing’s family tumours. Eur J Cancer. 2007;43:885–890.
11. Kamalakar P, Freeman AI, Highy DJ, et al. Clinical response and toxicity with cis-dichlorodiammineplatinum (II) in children. Cancer Treat Rep. 1977;61:835–839.
12. Nitschke R, Starling KA, Vats T, et al. Cis-diaminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Med Pediatr Oncol. 1978;4:127–132.
13. Baum ES, Gaynon P, Greenberg L, et al. Phase II trial cisplatin in refractory childhood cancer: Children’s Cancer Study Group Report. *Cancer Treat Rep.* 1981;65:815–822.

14. Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. *Cancer Treat Rep.* 1981;65:1021–1026.

15. Matsumoto S, Kawaguchi N, Amino K, et al. Combination chemotherapy including cis-platinum in Ewing’s sarcoma. *Gan To Kagaku Ryoho.* 1987;14:1913–1916.

16. Luksch R, Massimino M, Cefalo G, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in an intensive treatment program for children with Ewing’s sarcoma. *Haematologica.* 2001;86:753–760.

17. Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children’s Hospital experience. *Cancer.* 2006;106:1838–1845, 15.